FAQ

OGX-011

Known as: ISIS 112989 
A mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. OGX-011 inhibits testosterone-repressed prostate message-2 (TRPM-2… (More)

Topic mentions per year

Topic mentions per year

2004-2016
024620042016

Related topics

Related topics

3 relations

Broader (2)

Thionucleotidesclusterin antisense oligonucleotide

Narrower (1)

custirsen

Related mentions per year

Related mentions per year

1972-2017
197019801990200020102020
OGX-011
custirsen
clusterin antisense oligonucleotide
Thionucleotides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma
PURPOSE Despite recent improvements in therapeutic management of osteosarcoma, ongoing challenges in improving the response to… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
Background:The objective of this study was to investigate whether the therapeutic activity of sorafenib could be enhanced by… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
Small-molecule inhibitors of Hsp90 show promise in the treatment of castrate-resistant prostate cancer (CRPC); however, these… (More)
Is this relevant?
2011
2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after…
PURPOSE Clusterin (CLU) is an antiapoptotic, stress-induced protein conferring treatment resistance when overexpressed. This… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
PURPOSE To determine the clinical activity of OGX-011, an antisense inhibitor of clusterin, in combination with docetaxel… (More)
  • figure 1
  • table 2
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2009
2009
Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer.
PURPOSE Clusterin is an antiapoptotic protein activated in response to cellular stress. OGX-011 is a second-generation antisense… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • table 2
Is this relevant?
2009
2009
Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer.
5012 Background: Clusterin is a cytoprotective chaperone protein associated with CRPC progression. OGX is a 2'-methoxyethyl… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
OBJECTIVES To characterize changes in secretory clusterin (sCLU) expression in prostate cancer cells after treatment with… (More)
Is this relevant?
2008
2008
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
PURPOSE Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
BACKGROUND Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment… (More)
Is this relevant?